BACKGROUND & AIMS: Adenoviral (Ad) vectors are currently one of the most efficient tools for in vivo gene transfer to the liver. However, anti-Ad immune responses limit the safety and efficacy of these vectors. The initial inflammatory reaction is a concern in terms of toxicity, and it favours the development of cellular and humoral responses leading to short transgene persistence and inefficient vector re-administrations. Therefore, safe and simple ways to interfere with these processes are needed. Study ways to deplete specific immune cell populations and their impact on liver-directed gene transfer. METHODS: First-generation Ad vectors encoding reporter genes (luciferase or β-galactosidase) were injected intravenously into Balb/c mice. Kupffer cells and splenic macrophages were depleted by intravenous administration of clodronate liposomes. B lymphocytes, CD4(+) , CD8(+) T lymphocytes or NK cells were depleted by intraperitoneal injection of anti-M plus anti-D, anti-CD4, anti-CD8 or anti-asialo-GM1 antibodies respectively. Long-term evolution of luciferase expression in the liver was monitored by bioluminescence imaging. RESULTS: The anti-CD4 monoclonal antibody impaired cellular and humoral immune responses, leading to efficient vector re-administration. Clodronate liposomes had no impact on humoral responses but caused a 100-1000 fold increase in liver transduction, stabilized transgene expression, reduced the concentration of inflammatory cytokines, and inhibited lymphocyte activation. CONCLUSIONS: Transient CD4(+) T-cell depletion using antibodies is a clinically feasible procedure that allows efficient Ad redosing. Systemic administration of clodronate liposomes may further increase the safety and efficacy of vectors.
BACKGROUND & AIMS: Adenoviral (Ad) vectors are currently one of the most efficient tools for in vivo gene transfer to the liver. However, anti-Ad immune responses limit the safety and efficacy of these vectors. The initial inflammatory reaction is a concern in terms of toxicity, and it favours the development of cellular and humoral responses leading to short transgene persistence and inefficient vector re-administrations. Therefore, safe and simple ways to interfere with these processes are needed. Study ways to deplete specific immune cell populations and their impact on liver-directed gene transfer. METHODS: First-generation Ad vectors encoding reporter genes (luciferase or β-galactosidase) were injected intravenously into Balb/c mice. Kupffer cells and splenic macrophages were depleted by intravenous administration of clodronate liposomes. B lymphocytes, CD4(+) , CD8(+) T lymphocytes or NK cells were depleted by intraperitoneal injection of anti-M plus anti-D, anti-CD4, anti-CD8 or anti-asialo-GM1 antibodies respectively. Long-term evolution of luciferase expression in the liver was monitored by bioluminescence imaging. RESULTS: The anti-CD4 monoclonal antibody impaired cellular and humoral immune responses, leading to efficient vector re-administration. Clodronate liposomes had no impact on humoral responses but caused a 100-1000 fold increase in liver transduction, stabilized transgene expression, reduced the concentration of inflammatory cytokines, and inhibited lymphocyte activation. CONCLUSIONS: Transient CD4(+) T-cell depletion using antibodies is a clinically feasible procedure that allows efficient Ad redosing. Systemic administration of clodronate liposomes may further increase the safety and efficacy of vectors.
Authors: J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba Journal: Gene Ther Date: 2015-05-04 Impact factor: 5.250
Authors: Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth Journal: J Virol Date: 2017-04-28 Impact factor: 5.103
Authors: Tuuli Ranki; Sari Pesonen; Akseli Hemminki; Kaarina Partanen; Kalevi Kairemo; Tuomo Alanko; Johan Lundin; Nina Linder; Riku Turkki; Ari Ristimäki; Elke Jäger; Julia Karbach; Claudia Wahle; Matti Kankainen; Charlotta Backman; Mikael von Euler; Elina Haavisto; Tiina Hakonen; Raita Heiskanen; Magnus Jaderberg; Juuso Juhila; Petri Priha; Laura Suoranta; Lotta Vassilev; Antti Vuolanto; Timo Joensuu Journal: J Immunother Cancer Date: 2016-03-15 Impact factor: 13.751
Authors: Aritz Lasarte-Cia; Teresa Lozano; Marta Pérez-González; Marta Gorraiz; Kristina Iribarren; Sandra Hervás-Stubbs; Pablo Sarobe; Obdulia Rabal; Mar Cuadrado-Tejedor; Ana García-Osta; Noelia Casares; Juan José Lasarte Journal: Front Immunol Date: 2018-01-25 Impact factor: 7.561
Authors: Sam Illingworth; Ying Di; Maxine Bauzon; Janet Lei; Margaret R Duffy; Simon Alvis; Brian Champion; André Lieber; Terry Hermiston; Len W Seymour; John Beadle; Kerry Fisher Journal: Mol Ther Oncolytics Date: 2017-03-29 Impact factor: 7.200